rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
1993-4-8
|
pubmed:abstractText |
Twenty-three stabilized chronic uremic patients with no active or recent infection were treated for 10 days with either cefodizime (5 x 2 g intravenously, n = 10) or cotrimoxazole (960 mg orally b.i.d., n = 8) in order to evaluate the effects on the depressed polymorphonuclear metabolic response to phagocytic challenge; a separate group of 5 patients received placebo. Ex vivo evaluation in whole blood of energy delivery to the phagocytosis-associated respiratory burst activity in response to latex and zymosan challenge was determined by measuring hexose-monophosphate shunt NAD(P)H-oxidase-related glycolytic activity. Cefodizime induced a statistically significant increase in the baseline-depressed glycolytic response for both latex and zymosan challenge, in contrast to cotrimoxazole and placebo. Depressed phagocytosis-related metabolic function in hemodialyzed patients was stimulated by cefodizime in recommended therapeutic doses but not by cotrimoxazole, the effect persisting for at least 2 weeks after the end of treatment.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0028-2766
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
63
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
65-72
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8446254-Adult,
pubmed-meshheading:8446254-Aged,
pubmed-meshheading:8446254-Cefotaxime,
pubmed-meshheading:8446254-Chronic Disease,
pubmed-meshheading:8446254-Dose-Response Relationship, Drug,
pubmed-meshheading:8446254-Energy Metabolism,
pubmed-meshheading:8446254-Female,
pubmed-meshheading:8446254-Glycolysis,
pubmed-meshheading:8446254-Humans,
pubmed-meshheading:8446254-Injections, Intravenous,
pubmed-meshheading:8446254-Latex,
pubmed-meshheading:8446254-Male,
pubmed-meshheading:8446254-Middle Aged,
pubmed-meshheading:8446254-NADH, NADPH Oxidoreductases,
pubmed-meshheading:8446254-NADPH Oxidase,
pubmed-meshheading:8446254-Neutrophils,
pubmed-meshheading:8446254-Phagocytes,
pubmed-meshheading:8446254-Phagocytosis,
pubmed-meshheading:8446254-Renal Dialysis,
pubmed-meshheading:8446254-Respiratory Burst,
pubmed-meshheading:8446254-Time Factors,
pubmed-meshheading:8446254-Trimethoprim-Sulfamethoxazole Combination,
pubmed-meshheading:8446254-Uremia,
pubmed-meshheading:8446254-Zymosan
|
pubmed:year |
1993
|
pubmed:articleTitle |
Antibiotics and energy delivery to the phagocytosis-associated respiratory burst in chronic hemodialysis patients: a comparison of cefodizime and cotrimoxazole.
|
pubmed:affiliation |
Nephrology Department, University Hospital, Ghent, Belgium.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial
|